← Product Code [NDN](/submissions/OR/subpart-d%E2%80%94prosthetic-devices/NDN) · K102397 # KYPHON XPEDE BONE CEMENT (K102397) _Medtronic · NDN · Feb 28, 2011 · Orthopedic · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/OR/subpart-d%E2%80%94prosthetic-devices/NDN/K102397 ## Device Facts - **Applicant:** Medtronic - **Product Code:** [NDN](/submissions/OR/subpart-d%E2%80%94prosthetic-devices/NDN.md) - **Decision Date:** Feb 28, 2011 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 888.3027 - **Device Class:** Class 2 - **Review Panel:** Orthopedic - **Attributes:** Therapeutic ## Intended Use KYPHON® Xpede™ Bone Cement is indicated for the treatment of pathological fractures of the vertebral body due to osteoporosis, cancer, or benign lesions using a kyphoplasty or vertebroplasty procedure. Cancer includes multiple myeloma and metastatic lesions, including those arising from breast or lung cancer, or lymphoma. Benign lesions include hemangioma and giant cell tumor. ## Device Story Two-component PMMA bone cement system; powder component (PMMA copolymer, barium sulfate radiopacifier, benzoyl peroxide initiator) mixed with liquid component (methylmethacrylate monomer, hydroquinone stabilizer, N,N-dimethyl-p-toluidine promoter) prior to use. Used by physicians during kyphoplasty or vertebroplasty procedures to stabilize vertebral fractures. Provides structural support to the vertebral body. Single-use, sterile device. ## Clinical Evidence Bench testing only. No clinical data provided. Testing included mechanical, handling, physical, chemical, and biocompatibility assessments to verify performance for in vivo applications. ## Technological Characteristics Two-component PMMA bone cement. Powder: PMMA copolymer, barium sulfate, benzoyl peroxide. Liquid: methylmethacrylate monomer, hydroquinone, N,N-dimethyl-p-toluidine. Sterile, single-use. No electronic or software components. ## Regulatory Identification Polymethylmethacrylate (PMMA) bone cement is a device intended to be implanted that is made from methylmethacrylate, polymethylmethacrylate, esters of methacrylic acid, or copolymers containing polymethylmethacrylate and polystyrene. The device is intended for use in arthroplastic procedures of the hip, knee, and other joints for the fixation of polymer or metallic prosthetic implants to living bone. ## Special Controls *Classification.* Class II (special controls). The special control for this device is the FDA guidance document entitled “Class II Special Controls Guidance Document: Polymethylmethacrylate (PMMA) Bone Cement.” ## Predicate Devices - KyphX HV-R® Bone Cement ([K093829](/device/K093829.md)) - KyphX HV-R® Bone Cement ([K041584](/device/K041584.md)) - KyphX HV-R® Bone Cement ([K033801](/device/K033801.md)) - Confidence High Viscosity Bone Cement ([K060300](/device/K060300.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ K102397 FEB 28 2011 # 510(k) Summary for Kyphon® Xpede™ Bone Cement | Summary Date: | December 2010 | |----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | Trade Name: | Kyphon® Xpede™ Bone Cement | | Common Name: | PMMA Bone Cement | | Classification Name: | Bone Cement (21 CFR part 888.3027) | | Device Code, Class: | NDN, Class II | | Manufacturer's Name:
Address: | Medtronic Spine LLC
1221 Crossman Avenue
Sunnyvale, CA 94089
Establishment Registration No. 2953769 | | Contact Person: | Mary Rose
Sr. Principal Regulatory Affairs Specialist
1221 Crossman Avenue
Sunnyvale, CA 94089
Telephone: 408-548-5203
Fax: 408-543-6190 | | Performance Standards: | The requirements of the Food Drug and Cosmetic Act,
under section 514 for performance standards, are not
applicable to the KyphX HV-R® Bone Cement. | | Predicate Devices: | K093829 KyphX HV- R® Bone Cement
K041584 KyphX HV- R® Bone Cement
K033801 KyphX HV- R® Bone Cement
K060300 Confidence High Viscosity Bone Cement | | Intended Use: | KYPHON® Xpede™ Bone Cement is indicated for the
treatment of pathological fractures of the vertebral body
due to osteoporosis, cancer, or benign lesions using a
kyphoplasty or vertebroplasty procedure. Cancer
includes multiple myeloma and metastatic lesions,
including those arising from breast or lung cancer, or
lymphoma. Benign lesions include hemangioma and
giant cell tumor. | | Device Description: | KYPHON® Xpede™ Bone Cement is provided as a two-
component system. The powder component consists of a
PMMA copolymer (polymethyl methacrylate/methyl-
methacrylate-styrene-copolymer) with barium sulfate as
a radiopacifier and benzoyl peroxide as an initiator. The
liquid component consists of methylmethacrylate
monomer, with the addition of hydroquinone as a
stabilizer and N,N-dimethyl-p-toluidine as a promoter.
The powder and liquid components are mixed prior to
use. | | Sterilization: | KYPHON® Xpede™ Bone Cement is provided sterile.
KYPHON® Xpede™ Bone Cement is intended for single-
use only. | | Substantial Equivalence: | Testing was conducted to verify the performance of
Kyphon® Xpede™ Bone Cement for in vivo applications. | | | The following testing was conducted:
- Mechanical (compressive, tensile, flexural, fatigue)
- Handling (dough/working time)
- Physical (viscosity, exotherm, water absorption)
- Chemical (monomer elution, molecular weight, glass
transition temperature)
- Biocompatibility (cytotoxicity, acute systemic
toxicity, intracutaneous reactivity) | | | The results of this testing support the determination of
substantial equivalence. | | | Therefore, the modified Kyphon® Xpede™ Bone Cement | {1}------------------------------------------------ ## 510(k) Summary for Kyphon® Xpede™ Bone Cement is substantially equivalent to the predicates, Kyphon HV-R Bone Cement, and Confidence High Viscosity Bone Cement. {2}------------------------------------------------ Image /page/2/Picture/0 description: The image shows the seal of the Department of Health & Human Services USA. The seal is circular, with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" arranged around the perimeter. In the center of the seal is a stylized eagle with its wings spread. The eagle is facing to the right and has its head turned to the left. ### DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002 Medtronic Spine LLC % Ms. Mary Rose Sr. Principal Regulatory Affairs Specialist 1221 Crossman Avenue Sunnyvale, California 94089 FEB 2 8 251 Re: K102397 Trade/Device Name: KYPHON® Xpede Bone Cement Regulation Number: 21 CFR 888.3027 Regulation Name: Polymethylmethacrylate (PMMA) bone cement Regulatory Class: Class II Product Code: NDN Dated: February 22, 2011 Received: February 23, 2011 Dear Ms. Rose: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordiner with the provisions of the Federal Food, Drug, and Cosmetic Act (Act (Act that do not require approval of the Federal Food, Drug, You may, therefore, market the dovice, subject to the premarket approval application (PMA) You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act {3}------------------------------------------------ ### Page 2 - Ms. Mary Rose or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting and listing); device-related adverse events (21 CFR Part 801); medical device reporting of medi device-related adverse events) (21 CFR 803); good manufacturing (reporting of medical forth in the quality systems (QS) requestion (11 OFR 803); good manufacturing as set forth in the quality systems (QS) regulation (2) CFR Part 820); and if a pplicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/Offices/Offices/Uploms/Splays/Classes the Center for Devices and Radiological Heolth.in CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health s (CDRH's) Office of Compliance. Also, him for note the regulation entitled. "Mishranding by references of Compliance. Also, p note the regulation entitled, "Misbranding by reference to premarket notification" (21.00) 807.97). For questions regarding the reporting of remarket notification" (21CFR Pa and of the same of the standing by relection of adverse events undification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR reg CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportalProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll the more of the more of its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet and Consum http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. .mcdermott.com/ICES/ResourcesforYou/Industry/default.htm. Sincerely yours. Aing B rh fr Mark N. Melkerson Director Division of Surgical, Orthopedic And Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {4}------------------------------------------------ ### Indications for Use 510(k) Number (if known): KYPHON® Xpede Bone Cement Device Name: #### Indications for Use: Kyphon® Xpede™ Bone Cement is indicated for the treatment of pathological fractures of the vertebral body due to osteoporosis, cancer, or benign lesions using a kyphoplasty or vertebroplasty procedure. Cancer includes multiple myeloma and metastatic lesions, including those arising from breast or lung cancer, or lymphoma. Benign lesions include hemangioma and giant cell tumor. Prescription Use V (Part 21 CFR 801 Subpart D) AND/OR Over-The-Counter Use (21 CFR 801 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) (Divisio (Division Sign-of Surgical, Orthopedic, and Restorative Devices Page _________________________________________________________________________________________________________________________________________________________________________ of 510(k) Number K102397 --- **Source:** [https://fda.innolitics.com/submissions/OR/subpart-d%E2%80%94prosthetic-devices/NDN/K102397](https://fda.innolitics.com/submissions/OR/subpart-d%E2%80%94prosthetic-devices/NDN/K102397) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com